Amsterdam, 31 October 2005 - Elsevier, a world-leading healthcare and scientific publisher, announced today that it is developing a suite of business intelligence solutions for the pharmaceutical and biotech market. To meet the demanding requirements of business intelligence, market research and business development professionals, Elsevier is developing customizable, integrated products that will provide the information they need to make informed business decisions.
Working in cooperation with AdvantTechnologies (aTi), Elsevier is developing a suite of business intelligence solutions to include a database of drugs in clinical development, consulting and syndicated reports. The database will be launched to the market in early 2006.
"Our position as a leading publisher of quality, peer-reviewed content and our key opinion leader network, coupled with aTi's technology means we can deliver business intelligence solutions pharmaceutical and biotech professionals can trust," says Brian Nairn, CEO of Elsevier, Health Sciences. "To ensure we deliver products that will give them confidence in the information they receive, we've solicited the input of a group of seasoned industry advisors and we're investing in extensive user testing."
Elsevier's business intelligence product development drive will be lead by newly appointed Director of Emerging Products, Julie Gordon. "We've conducted qualitative research with pharmaceutical and biotech professionals throughout North America, Europe and Japan. The respondents told us there's a demand for business intelligence solutions that are accurate, timely and focused," says Gordon, "We are developing a suite of products that are flexible and modular so that users can easily and efficiently mine the data they need, when they need it."
# # #
About AdvanTechnologies Inc.
Founded by world-renowned IT researchers, AdvanTechnologies (aTi) provides state-of-the-art Knowledge Management Enabling software products and associated decision support tools targeted to the pharmaceutical, biomedical and healthcare industries. For more information visit www.advantechnologies.com.
About Elsevier
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. Working in partnership with the global science and health communities, Elsevier's 7,000 employees in over 70 offices worldwide publish more than 2,000 journals and 1,900 new books per year, in addition to offering a suite of innovative electronic products, such as ScienceDirect, MD Consult , Scopus, bibliographic databases, and online reference works.
Elsevier is a global business headquartered in Amsterdam, The Netherlands and has offices worldwide. Elsevier is part of Reed Elsevier Group plc, a world-leading publisher and information provider. Operating in the science and medical, legal, education and business-to-business sectors, Reed Elsevier provides high-quality and flexible information solutions to users, with increasing emphasis on the Internet as a means of delivery. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Media Contact:
Paula Reeves
The Reeves Agency
paula@thereevesagency.com
Tel. +31-(0)20-3051380
